Gene Therapy Updates

FDA grants priority review for Biomarin’s hemophilia A gene therapy

San Rafael, California, February 21, 2020 – Biomarin Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has granted a priority review for its hemophilia A gene therapy valoctocogene roxaparvovec, commonly called valrox. This means that the FDA may rule on approving the therapy by August 21, 2020.

Biomarin announced results last year from the Phase 3 cohort of its pivotal study:

  • eight of 16 participants had reached or exceeded factor VIII expression levels of 40%;
  • all 16 patients who were at least 26 weeks post-treatment had an estimated median annual bleed rate of zero.

Also in February, Clarivate Analytic released a report forecasting that if approved, the list price for the one-time valrox treatment could be $2.5-3 million U.S.

Biomarin has not submitted a request for licensure in Canada.

Pfizer is also competing in the hemophilia A gene therapy space with its Sangamo Therapeutics-originated SB-525, just now entering Phase III trials.

Freeline presents early data on hemophilia B gene therapy

London, February 7, 2020 – Freeline presented data from its Phase 1/2 B-AMAZE trial of its novel gene therapy, FLT180a, for hemophilia B at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorder (EAHAD), in The Hague, Netherlands.

“The data presented at EAHAD are promising, with eight patients treated in a 4-dose cohort study, and the early data for the fourth dose cohort of 9.75 × 1011 vector genomes (vg)/kg suggests the potential to deliver FIX activity between 70-150%, the upper part of the normal range,” said Chris Hollowood, Executive Chairman of Freeline.

The program aims to achieve normal FIX activity levels (50-150%), which would mean that patients would not need FIX concentrates following trauma or surgery. FLT180a uses the company’s proprietary AAVS3 capsid. Each person in the trial received a prophylactic regimen of steroids post administration to modulate an immune response in the liver to the AAV vector and maintain gene expression.

Two other hemophilia B gene therapies are already well into Phase 3 clinical trials: Pfizer’s fidanacogene elaparvovec, licensed from Roche subsidiary Spark Therapeutics, and UniQure’s etranacogene dezaparvovec.

Canadian Hemophilia Society
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.